September 2002, Volume 16, Number 9, Pages 1622-1626 Table of contents Previous Abstract Next Full text PDF Original Manuscript Acute megakaryoblastic leukemia: experience of GIMEMA trials L Pagano1, A Pulsoni2, M Vignetti2, L Mele1, L Fianchi1, M C Petti2, S Mirto4, P Falcucci2, P Fazi2, G Broccia12, G Specchia7, F Di Raimondo11, L Pacilli9, P Leoni13, S Ladogana8, E Gallo3, A Venditti6, G Avanzi10, A Camera5, V Liso7, G Leone1 and F Mandelli2 for the GIMEMA 1Cattedra di Ematologia, Università Cattolica S. Cuore, Roma, Italy 2Dipartimento di Biotecnologie cellulari ed Ematologia, Università 'La Sapienza', Roma, Italy 3Ematologia Molinette, Ospedale Maggiore 'S Giovanni Battista', Torino, Italy 4Divisione di Ematologia, Ospedale Cervello di Palermo, Italy 5Divisione di Ematologia, II Policlinico, Napoli, Italy 6Istituto di Ematologia, Università di Tor Vergata, Roma, Italy 7Istituto di Ematologia, Università di Bari, Bari, Italy 8Divisione di Ematologia, Ospedale di S Giovanni Rotondo, Italy 9Divisione di Ematologia, Ospedale S Camillo, Roma, Italy 10Divisione di Ematologia, Ospedale di Novara, Italy 11Cattedra di Ematologia, Università di Catania, Italy 12Divisione di Ematologia, Ospedale Cagliari, Italy 13Cattedra di Ematologia, Università di Ancona, Italy Correspondence to: L Pagano, Dept of Haematology, Catholic University, Largo Francesco Vito 1, I-00168 Roma, Italy; Fax: 39063051343 Abstract The objective of the study was to evaluate the incidence, characteristics, treatment and outcome of acute megakaryoblastic leukemia (AMeL) in patients enrolled in GIMEMA trials. Between 1982 and 1999, 3603 new consecutive cases of AML aged over 15 years were admitted to GIMEMA trials. Of them, 24 were AMeL. The incidence of AMeL among AML patients enrolled in GIMEMA trials was 0.6% (243603). Diagnosis was based on morphological criteria. Out of 11 cytogenetic studies performed two presented chromosome 3 abnormalities. Twelve patients (50%) reached a CR, five (21%) died in induction and seven (27%) were unresponsive. The median duration of CR was 35 weeks (range 10441). Seven patients underwent transplantation procedures (1 BMT, 4 aBMT, 2 aPBSCT). Four patients died in CR due to chemotherapy-related complications. Comparing the CR rate between AMeL and the other cases of AML enrolled in GIMEMA trials, no differences were observed. These results were mirrored for different age groups. The median survival was 40 weeks. At present, after a follow-up of a minimum of 2 years, only two patients are alive in CR, all the others having died. A 5-year KaplanMeier curve shows a disease-free survival of 17% and an actuarial overall survival of 10%. AMeL is a rare form of AML. The CR duration and the overall survival in this group of patients are very poor, even if similar to those observed in other AML. Furthermore, a high number of deaths in CR were observed. On the basis of these data, a specific therapeutic approach, possibly with innovative treatments, should be evaluated. Leukemia (2002) 16, 16221626. doi:10.1038/sj.leu.2402618

Acute megakaryoblastic leukemia: experience of GIMEMA trials

LEONI, Pietro;
2002-01-01

Abstract

September 2002, Volume 16, Number 9, Pages 1622-1626 Table of contents Previous Abstract Next Full text PDF Original Manuscript Acute megakaryoblastic leukemia: experience of GIMEMA trials L Pagano1, A Pulsoni2, M Vignetti2, L Mele1, L Fianchi1, M C Petti2, S Mirto4, P Falcucci2, P Fazi2, G Broccia12, G Specchia7, F Di Raimondo11, L Pacilli9, P Leoni13, S Ladogana8, E Gallo3, A Venditti6, G Avanzi10, A Camera5, V Liso7, G Leone1 and F Mandelli2 for the GIMEMA 1Cattedra di Ematologia, Università Cattolica S. Cuore, Roma, Italy 2Dipartimento di Biotecnologie cellulari ed Ematologia, Università 'La Sapienza', Roma, Italy 3Ematologia Molinette, Ospedale Maggiore 'S Giovanni Battista', Torino, Italy 4Divisione di Ematologia, Ospedale Cervello di Palermo, Italy 5Divisione di Ematologia, II Policlinico, Napoli, Italy 6Istituto di Ematologia, Università di Tor Vergata, Roma, Italy 7Istituto di Ematologia, Università di Bari, Bari, Italy 8Divisione di Ematologia, Ospedale di S Giovanni Rotondo, Italy 9Divisione di Ematologia, Ospedale S Camillo, Roma, Italy 10Divisione di Ematologia, Ospedale di Novara, Italy 11Cattedra di Ematologia, Università di Catania, Italy 12Divisione di Ematologia, Ospedale Cagliari, Italy 13Cattedra di Ematologia, Università di Ancona, Italy Correspondence to: L Pagano, Dept of Haematology, Catholic University, Largo Francesco Vito 1, I-00168 Roma, Italy; Fax: 39063051343 Abstract The objective of the study was to evaluate the incidence, characteristics, treatment and outcome of acute megakaryoblastic leukemia (AMeL) in patients enrolled in GIMEMA trials. Between 1982 and 1999, 3603 new consecutive cases of AML aged over 15 years were admitted to GIMEMA trials. Of them, 24 were AMeL. The incidence of AMeL among AML patients enrolled in GIMEMA trials was 0.6% (243603). Diagnosis was based on morphological criteria. Out of 11 cytogenetic studies performed two presented chromosome 3 abnormalities. Twelve patients (50%) reached a CR, five (21%) died in induction and seven (27%) were unresponsive. The median duration of CR was 35 weeks (range 10441). Seven patients underwent transplantation procedures (1 BMT, 4 aBMT, 2 aPBSCT). Four patients died in CR due to chemotherapy-related complications. Comparing the CR rate between AMeL and the other cases of AML enrolled in GIMEMA trials, no differences were observed. These results were mirrored for different age groups. The median survival was 40 weeks. At present, after a follow-up of a minimum of 2 years, only two patients are alive in CR, all the others having died. A 5-year KaplanMeier curve shows a disease-free survival of 17% and an actuarial overall survival of 10%. AMeL is a rare form of AML. The CR duration and the overall survival in this group of patients are very poor, even if similar to those observed in other AML. Furthermore, a high number of deaths in CR were observed. On the basis of these data, a specific therapeutic approach, possibly with innovative treatments, should be evaluated. Leukemia (2002) 16, 16221626. doi:10.1038/sj.leu.2402618
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11566/73661
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact